DESCRIPTION: Fenofibric Acid is believed to increase VLDL catabolism by enhancing the synthesis of lipoprotein lipase; as a result of a decrease in VLDL levels, total plasma triglycerides are reduced by 30-60%; modest increase in HDL occurs in some hypertriglyceride patients.

INDICATION(S): Treatment of Hypertriglyceridemia
Treatment of Hypercholesterolemia or mixed Hyperlipidemia

REASONS FOR Step Therapy: ☒ Cost  ☐ Potential for misuse  ☐ Toxicity

CRITERIA for APPROVAL: The patient has had a trial and failure of generic Fenofibrate or Gemfibrizol

REASONS for DENIAL of BENEFIT: Patient does not meet above criteria.

BENEFIT APPROVAL: Approval for two year.